FIG. 5.

AML-1 binding to the TBLV LTR enhancer region. (A) Comparison of the AML-1 consensus sequence to that from TBLV, MuLVs, and the T-cell receptor alpha chain (TCRα). The AML-1 high-affinity site was selected as described previously (63). Sites shown are as reported by Lewis et al. (34). (B) Supershift experiments show AML-specific binding to the TBLV enhancer monomer element. The TBLV enhancer probe (556WT) was used for EMSA with whole-cell Jurkat extracts in lanes 1 to 6, whereas a known AML-1 binding site probe was used in lanes 7 to 12. Sequences of probes are shown in Fig. 6A. The NF-A complex (indicated by an arrow) and the AML-1 supershifted complex (indicated by an asterisk) migrate similarly on the gel. The AML-1 antibody (Ab) specificity has been demonstrated (44). Normal rabbit immunoglobulin G (IgG) was used as a negative control in lanes 3 and 9.